Research into psychedelics presents many logistical challenges, including regulatory hurdles, storing and handling requirements, and record-keeping. In an interview with Pharmacy Times, Mark Bleackley, PhD, chief scientific officer at Incannex Healthcare Limited in Melbourne, Australia, said patient subject...
summary the psychedelics sector has suffered a big blow, with the us fda knocking back a new drug application for mdma-assisted therapy. the potential for a negative fda decision had been well-flagged by an advisory committee report in june, so the market may have already priced ...
1. Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis. News release. Johnson and Johnson. August 29, 2024. Accessed August 29, 2024. https://www.jnj.com/media-center/press-releases/johnson-johnson-...
Pain is among the most widespread chronic health condition confronting society today and our inability to manage chronic pain contributes to the opioid abuse epidemic in America. The immune system is known to contribute to acute and chronic pain, but only limited therapeutic treatments such as non-...
Psychedelics CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) —Wesana Health Holdings Inc.(“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pl...
Pharmacy Focus: World Psychedelics Day Ashley Gallagher, Associate Editor November 1st 2024 Survey: 50% of Active Drug Shortages in the United States Persist for 2 or More Years Ashley Gallagher, Associate Editor June 7th 2024 Pharmacy Focus: The Role of Pharmacists in Promoting Mental Health Care...
Celum, MD, MPH, lead investigator of the Partners PrEP trial and professor of global health and medicine at the University of Washington, in a press release.“Although the implementation of PrEP will bring challenges, they can be anticipated and systems developed to address these challenges.” ...
Qato said. “One of the challenges in measuring and interpreting the effectiveness of FDA risk management tools is that we don't have established benchmarks for successful responsiveness.” There is no explanation at this time on the racial differences in drug discontinuation, but financial issues...